Blinatumomab

Common brands: Blincyto, Dexamethasone 1.5 Mg, Dexamethasone, Dextenza, Dexycu

Top reporter: Amgen, Inc

Corticosteroid [EPC]Folate Analog Metabolic Inhibitor [EPC]Nucleoside Metabolic Inhibitor [EPC]Alkylating Drug [EPC]CD22-directed Immunoconjugate [EPC]
10,115
Total Reports
5,954
Serious Reports
1,854
Death Reports
30
Reported Reactions
Death Report Ratio: High (18.33%)

Patient Demographics

Male
3,940
Female
3,444

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Blinatumomab.

# Reaction Reports % of Total
1 PYREXIA 1,135
10.6%
2 ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT 1,079
10.1%
3 CYTOKINE RELEASE SYNDROME 1,066
10.0%
4 OFF LABEL USE 711
6.7%
5 DEATH 644
6.0%
6 NEUROTOXICITY 574
5.4%
7 DRUG INEFFECTIVE 416
3.9%
8 HEADACHE 362
3.4%
9 NEUTROPENIA 311
2.9%
10 FEBRILE NEUTROPENIA 304
2.9%
11 THERAPY NON-RESPONDER 278
2.6%
12 TREMOR 271
2.5%
13 SEIZURE 258
2.4%
14 INFECTION 257
2.4%
15 ACUTE LYMPHOCYTIC LEUKAEMIA 241
2.3%
16 CONFUSIONAL STATE 222
2.1%
17 THROMBOCYTOPENIA 222
2.1%
18 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 202
1.9%
19 ACCIDENTAL EXPOSURE TO PRODUCT 197
1.8%
20 PRODUCT STORAGE ERROR 196
1.8%
21 PNEUMONIA 192
1.8%
22 SEPSIS 186
1.7%
23 DISEASE PROGRESSION 184
1.7%
24 LEUKAEMIC INFILTRATION EXTRAMEDULLARY 183
1.7%
25 CENTRAL NERVOUS SYSTEM LEUKAEMIA 181
1.7%
26 B PRECURSOR TYPE ACUTE LEUKAEMIA 166
1.6%
27 NERVOUS SYSTEM DISORDER 160
1.5%
28 HYPOTENSION 157
1.5%
29 ANAEMIA 156
1.5%
30 NAUSEA 155
1.5%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.